Hagop M. Kantarjian,
Francis Giles,
Norbert Gattermann,
Kapil Bhalla,
Giuliana Alimena,
Francesca Palandri,
Gert J. Ossenkoppele,
Franck-Emmanuel Nicolini,
Stephen G. O'Brien,
Mark Litzow,
Ravi Bhatia,
Francisco Cervantes,
Ariful Haque,
Yaping Shou,
Debra J. Resta,
Aaron Weitzman,
Andreas Hochhaus,
Philipp le Coutre,
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G.J., Nicolini, F.E., O'Brien, S.G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D.J., Weitzman, A., Hochhaus, A., le Coutre, P. Blood (2007)